ClinicalTrials.gg

Program

SR604

A development code.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.

Furthest: phase 3, since Oct 9, 20265 company-led studies, 5 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai RAAS Blood Products44 open or runningphase 3since Oct 9, 2026May 26, 2026Dec 31, 2026phase 2 · NCT07644832
Equilibra Bioscience11 open or runningphase 1since Mar 20, 2024Mar 20, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2024First study: phase 1 study in Hemophilia ANew to Equilibra BioscienceEquilibra Bioscience · NCT06349473 · 31 planned · United States, Canada
  2. May 26, 2026Shanghai RAAS Blood Products's first study: phase 2 study in Hemophilia ANew to Shanghai RAAS Blood ProductsShanghai RAAS Blood Products · NCT07644832 · 76 planned · China
  3. Jun 1, 2026Phase 2 study in von Willebrand DiseasesShanghai RAAS Blood Products · NCT07640893 · 24 planned · China
  4. Jul 14, 2026Phase 2 study in Factor VII DeficiencyShanghai RAAS Blood Products · NCT07711158 · 12 planned · China
  5. Oct 9, 2026Phase 3 study in Hemophilia APhase 3 reachedShanghai RAAS Blood Products · NCT07876674 · 90 planned

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Hemophilia AShanghai RAAS Blood Products · NCT07644832
  2. Feb 2027Primary completion: phase 2 study in Factor VII DeficiencyShanghai RAAS Blood Products · NCT07711158
  3. Sep 30, 2027Primary completion: phase 3 study in Hemophilia AShanghai RAAS Blood Products · NCT07876674
  4. Dec 31, 2027Primary completion: phase 2 study in von Willebrand DiseasesShanghai RAAS Blood Products · NCT07640893

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07876674Hemophilia A3Not yet recruitingShanghai RAAS Blood ProductsSep 30, 202790
NCT07711158Factor VII Deficiency · China2Not yet recruitingShanghai RAAS Blood ProductsFeb 202712
NCT07640893von Willebrand Diseases · China2RecruitingShanghai RAAS Blood ProductsDec 31, 202724
NCT07644832Hemophilia A · China2RecruitingShanghai RAAS Blood ProductsDec 31, 202676
NCT06349473Hemophilia A · United States, Canada1RecruitingEquilibra BioscienceSep 28, 202631

How it is read

Names in the registry

  • “SR604”, 7 entries

Codes read as this program: SR604.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.